Suzhou Kintor Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Sep 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 22, 2027The maintenance fee for Androgen receptor antagonists and uses thereof (US 9,216,957) comes due Jun 22, 2027. Unpaid by Dec 22, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
- Nov 17 US 12,799,091 Anhydrous Polymorphs of Androgen Receptor Antagonist, Preparation Method Therefor, and Use Thereof
- Oct 6 US 12,753,173 Amorphous Substances, Crystals, Pharmaceutical Compositions, Preparation Methods and Uses of Thiohydantoin Compound or Pharmaceutically Acceptable Salt Thereof
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,809,550 | Androgen receptor antagonists and uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,216,957 | Androgen receptor antagonists and uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,695,178 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof In force · USPTO record | In force | USPTO record | |
| US 10,919,889 | Chiral heterocyclic compound with hedgehog pathway antagonist activity, method and use thereof In force · USPTO record | In force | USPTO record | |
| US 11,242,346 | Mechanistic target of rapamycin signaling pathway inhibitors and therapeutic applications thereof In force · USPTO record | In force | USPTO record | |
| US 11,058,647 | Systems, methods, and kits for diagnostics and treatment of viral respiratory infection In force · USPTO record | In force | USPTO record | |
| US 12,606,552 | Bifunctional Compound, Preparation Method Therefor, and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,570,673 | C-Myc Protein Inhibitor, and Preparation Method Therefor and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,799,091 | Anhydrous Polymorphs of Androgen Receptor Antagonist, Preparation Method Therefor, and Use Thereof In force · High confidence | In force | High confidence | |
| US 12,753,173 | Amorphous Substances, Crystals, Pharmaceutical Compositions, Preparation Methods and Uses of Thiohydantoin Compound or Pharmaceutically Acceptable Salt Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 1 no status recorded